(Q35139161)

6 August 2017

1 reference

title

The role of chemotherapy in the current treatment of gastric cancer (English)

1 reference

6 August 2017

1 reference

1

Eric Van Cutsem

0 references

Atsushi Ohtsu

series ordinal

3

object named as

Atsushi Ohtsu

1 reference

6 August 2017

Daniel Haller

2

1 reference

6 August 2017

1 January 2002

1 reference

6 August 2017

1 reference

6 August 2017

5 Suppl 1

1 reference

6 August 2017

17-22

1 reference

https://scigraph.springernature.com/pub.10.1007/s10120-002-0219-y

6 August 2017

0 references

cites work

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-002-0219-Y

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-002-0219-Y

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-002-0219-Y

Developments in the treatment of gastric cancer in Europe

21 January 2018

1 reference

12 December 2020

Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen

1 reference

12 December 2020

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

12 December 2020

[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)]

1 reference

12 December 2020

Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies

1 reference

12 December 2020

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

12 December 2020

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

1 reference

12 December 2020

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

12 December 2020

Clinical trials for advanced gastrointestinal cancers in Japan. Japan Clinical Oncology Group Gastrointestinal Oncology Study Group

1 reference

12 December 2020

Laparoscopy, ultrasound and computed tomography in cancer of the oesophagus and gastric cardia: a prospective comparison for detecting intra-abdominal metastases.

1 reference

12 December 2020

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

12 December 2020

Advances in the therapy of gastric cancer

1 reference

12 December 2020

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

12 December 2020

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

1 reference

12 December 2020

[Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages]

1 reference

12 December 2020

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]

1 reference

12 December 2020

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

12 December 2020

Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials

1 reference

12 December 2020

Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

1 reference

12 December 2020

Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas

1 reference

12 December 2020

Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma

1 reference

12 December 2020

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

12 December 2020

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

12 December 2020

Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.

1 reference

12 December 2020

Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer

1 reference

12 December 2020

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

12 December 2020

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

1 reference

12 December 2020

10.1007/S10120-002-0219-Y

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12772882